Login to Your Account

Slow enrollment, vendor errors give AGTC black eye on Wall Street

By Marie Powers
News Editor

Tuesday, September 13, 2016

Shares of Applied Genetic Technologies Corp. opened sharply lower Tuesday and fell to a historic trough of $8.77 after the company reported slower than expected enrollment in phase I/II studies of its gene therapy candidates to treat the rare visual conditions XLRS and achromatopsia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription